Daiichi Sankyo Co Ltd

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Merck

Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates, the companies said on Thursday.

Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in multiple types of cancer at the 2023 European Society for Medical Oncology (#ESMO23) Congress to be held October 20 - 24, 2023. Three late-breaking abstracts, including two Presidential Symposia presentations, are among the more than 20 abstracts showcasing Daiichi Sankyo's leadership and progress in developing new standards of care for pa.

Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO

AstraZeneca

AstraZeneca said on Friday the European Medicines Agency's human medicines committee recommended its and Daiichi Sankyo's Enhertu drug as a monotherapy to treat patient with a type of non-small cell lung cancer (NSCLC).

EU recommends approval of AstraZeneca and Daiichi's drug for a type of lung cancer

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced results from two prespecified analyses from the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial. The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with di.

New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC.

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2023 Earnings Conference Call July 31, 2023 2:00 AM ET Company Participants Kentaro Asakura - Vice President of Corporate Communications Department Koji Ogawa - Executive Officer and Chief Financial Officer Wataru Takasaki - Executive Officer, Head of Research and Development Unit Ken Takeshita - Head of Global Research and Development Conference Call Participants Shinichiro Muraoka - Morgan Stanley Seiji Wakao - JPMorgan Hidemaru Yamaguchi - Citigroup Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit Suisse Kentaro Asakura [Foreign Language] Thank you very much for waiting. From now on, we would like to start Daiichi Sankyo FY2023 Q1 Financial Results Presentation.

Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Call Transcript

A Japanese health ministry panel recommended approval for Daiichi Sankyo's mRNA-based COVID-19 vaccine in what would be the nation's first home-grown shot for the coronavirus.

Japan's Daiichi Sankyo gets approval for COVID vaccine, first for country

The U.S. Food and Drug Administration (FDA) approved Japan-based Daiichi Sankyo Co's treatment for newly diagnosed patients with an aggressive type of blood cancer, the company said on Thursday, pitting it against rival drugs from Novartis and Astellas Pharma.

Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment

Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in cancer after more than a decade of ups and downs. The company stands poised to continue to stretch its arms in the space and reap significant growth.

Daiichi Sankyo: There Is A Lot Of Room To Grow

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA.

Daiichi Sankyo Showcases Latest Research Towards Creating New Standards of Care for Patients with Cancer with Data at ASCO and EHA

Japanese drugmaker Daiichi Sankyo said on Monday it will invest around 400 million reais ($80 million) to expand its Brazilian operations, part of a plan to boost its healthcare unit including launching new products in the coming years.

Japan's Daiichi Sankyo invests $80 million to expand Brazilian plant

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2022 Results Conference Call April 27, 2023 4:30 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Ken Takeshita - Global Head of Research and Development Conference Call Participants Hidemaru Yamaguchi - Citigroup Seiji Wakao - JPMorgan Securities Kazuaki Hashiguchi - Daiwa Securities Shinichiro Muraoka - Morgan Stanley Akinori Ueda - Goldman Sachs Securities Hiroyuki Okuzawa This is Okuzawa speaking. Thank you for attending Daiichi Sankyo's Financial Results for briefing despite your busy schedule.

Daiichi Sankyo Company, Limited (DSKYF) Q4 2022 Earnings Call Transcript

Updated results from phase 1 trial, including first presentation of data from a cohort of patients with EGFR-mutated metastatic non-small cell lung cancer, featured during a Presidential Session at JSMO

Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in Distinct Patient Populations with Metastatic Lung and Breast Cancer in Updated Results of Two Early Trials

BASKING RIDGE, N.J.--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) today announced that the new dosing regimen for TURALIO® (pexidartinib) is now available in the U.S. for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. A new 125 mg capsule of TURALIO is now available and the 200 mg capsule has been discontinued.

TURALIO® New Dosing Regimen Now Available in the U.S. for Certain Patients with Tenosynovial Giant Cell Tumor

FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer.

AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet)

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

argenx

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

BASKING RIDGE, N.J.--( BUSINESS WIRE )--Daiichi Sankyo (TSE: 4568) continues to boldly challenge the breast cancer treatment landscape with the presentation of 30 abstracts from its innovative DXd antibody drug conjugate (ADC) portfolio at the 2022 San Antonio Breast Cancer Symposium (#SABCS22) to be held December 6 to 10, 2022.

Data Across Daiichi Sankyo DXd ADC Portfolio at 2022 SABCS Demonstrates Bold Progress in Advancing Treatment for Patients with Breast Cancer

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2022 Results Conference Call October 31, 2022 1:30 AM ET Company Participants Sunao Manabe - Representative Director, President and CEO Wataru Takasaki - Head, R&D Division Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley Kazuaki Hashiguchi - Daiwa Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Fumiyoshi Sakai - Credit Suisse Sunao Manabe Manabe speaking. Thank you very much for joining Daiichi Sankyo's financial results presentation out of your very busy schedule today.

Daiichi Sankyo Company, Limited (DSKYF) Q2 2022 Earnings Call Transcript

MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO

Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2022 Earnings Conference Call July 29, 2022 2:00 AM ET Company Participants Hiroyuki Okuzawa - Head, Corporate Planning and Management Division, CFO Wataru Takasaki - Executive Officer, Head, R&D Division Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Seiji Wakao - JPMorgan Securities Shinichiro Muraoka - Morgan Stanley MUFG Securities Fumiyoshi Sakai - Crédit Suisse Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Kazuaki Hashiguchi - Daiwa Securities Hiroyuki Okuzawa Okuzawa speaking. Thank you very much for joining Daiichi Sankyo's Financial Results Presentation out of your very busy schedule today.

Daiichi Sankyo Company, Limited (DSKYF) Q1 2022 Results - Earnings Call Transcript

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) confirmed today that the U.S. District Court for the Eastern District of Texas has entered judgment on the April 8, 2022 jury verdict finding that ENHERTU® infringes Seagen's U.S. Patent 10,808,039 (the '039 patent), that the infringement was willful, and awarding Seagen $41.8 million in damages. Despite the jury's finding of willfulness, the Court decided under the totality of the c

Daiichi Sankyo Confirms that a Texas Court has Entered Judgment on the Jury Verdict in Seagen Patent Dispute

TOKYO & MUNICH--(BUSINESS WIRE)--Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2+ mBC Treated with a Prior Anti-HER2-Based Regimen

Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Investors will want to keep an eye on developments at this week's meeting of the American Society of Clinical Oncology in Chicago, where four members of big pharma will share study results of their most promising cancer drugs. The news has the potential to move the shares of the presenters-- Daiichi Sankyo Co. Ltd.

ASCO Presentations Could Move Shares of Daiichi, AstraZeneca, Gilead and Roche

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today multiple data presentations at the European Atherosclerosis Society (EAS) Congress 2022, highlighting the need to address current clinical perceptions and classification of risk of developing or exacerbating cardiovascular disease (CVD).1,2 Latest data from SANTORINI, a multinational, prospective, observational study designed to assess the management of high- and very high-risk CV patients requiring lipi

Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data presentations at EAS 2022

Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q4 2021 Results Conference Call April 27, 2022 3:30 AM ET Company Participants Hiroyuki Okuzawa - Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Executive Officer, Head of R&D Division Sunao Manabe - Representative Director, President and CEO Conference Call Participants Seiji Wakao - JPMorgan Securities Kazuaki Hashiguchi - Daiwa Securities Hidemaru Yamaguchi - Citigroup Securities Shinichiro Muraoka - Morgan Stanley Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Akinori Ueda - Goldman Sachs Securities Fumiyoshi Sakai - Crédit Suisse Securities Naoya Miura - Jefferies Sunao Manabe Manabe speaking. Thank you very much for joining Daiichi Sankyo's financial results presentation out of your very busy schedule today.

Daiichi Sankyo Company, Limited (DSKYF) CEO Sunao Manabe on Q4 2021 Results - Earnings Call Transcript

News for Daiichi Sankyo Co Ltd Stock (DSNKY)